A study was carried out to evaluate the reliability of and to determine the mechanism involved in an antigen extinction mouse intraperitoneal (ip) challenge test for potency of a cell culture vaccine for Japanese B encephalitis, a modification of a test originated by Sabin for a mouse brain vaccine. Some comparisons were made with the official Japanese test using an intracerebral (ic) challenge after a more prolonged immunization procedure. The Japanese method of using a lyophilized reference vaccine with each test was also employed. It was found that the ip and the ic test appeared to show similar relative differences between lots. The ip test was more quickly and readily performed, gave reasonably consistent results on repetition, and, when used with a suitable reference vaccine, gave promise of being an entirely suitable and reliable test. Immunization by the intramuscular route rather than by the regular ip route appeared to offer no advantage and was less consistent in responses shown. Neutralizing antibody responses of the mice in the standard procedure were very quick to appear, about 4 days after the first dose of vaccine and had a peak titer about the seventh day, the time of challenge. This titer fell quickly unless challenge occurred. The antibody was heat stable, but it was readily inactivated by 2-mercaptoethanol (2-ME). Not until the 11th or 15th day did a small amount of immunoglobulin G appear. Challenge on day 7 significantly increased titers, but this antibody was also mostly inactivated by 2-ME. Interferon did not appear to play any significant role in the protection shown by the mice.
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The mouse protection potency test for Japanese B encephalitis (JBE) vaccine was first described by Sabin et al. (12) and was later modified and accepted as a standard test by the Division of Biological Standards (DBS), National Institutes of Health (NIH, reference 10). Koprowski and Cox (8) criticized this test, questioning its significance for determining the potency of their chick embryo product. However, Smadel et al. (15) pointed out that the variations in range of minimal immunizing dose (MID) between 0.005 and 0.02 ml (fourfold) were of little significance in respect to potency as measured by antibody response in man. Darwish and Hammon (3) used this test with very slight modification and reported an inverse correlation between the MID and the preinactivated titers of different lots of vaccines prepared in a variety of ways. The higher the infectivity and HA titers the lower the MID of the inactivated vaccine. They found a rather wide range of experimental variability (far less than fourfold), but in most instances results were repeatable. The study reported here is based on work of the last several years during which further extensive testing of vaccine lots by the mouse potency test was done using, for much of the time, a lyophilized "standard" or "reference" vaccine with each test as a reference preparation not included in earlier requirements (10) ). Usually the Formalin-inactivated liquid vaccine was shell frozen in ampoules containing about 1.5-ml quantity. These were stored in a Revco at about -65 C, and at the time of use the ampoule was thawed by using a 37 C water bath. Vials of lyophilized vaccine were stored at -20 C. At the time of use, the latter preparation was rehydrated to its original volume by adding 2 ml of doubledistilled water.
Mouse potency test. The method of immunization and challenge of mice, both performed by the ip route, were as described by Darwish and Hammon (3) . Serial fourfold dilutions of the vaccine from 1/20 to 1/1,280 were prepared and 12 weanling mice weighing 18 to 22 g were inoculated twice at an interval of 3 Nagai and Hammon (9) . Plaques were counted after 4 days, and reciprocals of serum dilutions inhibiting 50% of the plaques were determined graphically.
To inactivate IgM antibody the serum samples were treated with 2-mercaptoethanol (2-ME).
Interferon assay. The interferon titers of serum pooled from six mice were determined by the technique of plaque inhibition assay as described previously (14) . The duplicate L-cell culture plates were inoculated with 2 ml of serum dilutions. After overnight incubation at 37 C under 5% CO2, the plates were drained and then challenged with about 200 plaque-forming units (PFU) of vesicular stomatitis virus (13) . The serum dilutions inhibiting 50% of the plaques were calculated by plotting reciprocals of the serum dilutions against the percentage of plaques reduced.
RESULTS
Repeatability of mouse challenge test. Several vaccine lots prepared and stored at -65 C were tested more than once. Results of mouse potency tests on six such lots are shown in Table 1 . Vaccine lots 1-4 were tested at different intervals ranging from 1 to 8 months. In case of vaccine lots 2, 5, and 6, two sets of mice were immunized with the same vaccine on the same day and then challenged with a similar dose by the standard method. Vaccine lot 3 was tested three times. The results of second and third tests were the same and differed only by 0.001 ml from the first test. The repeated tests on other vaccine lots also gave very similar results. As shown in Table 1 , the maximum variation in the MID on these lots when tested on the same day or at various intervals was 0.003 ml.
The total data on the lyophilized vaccine which was used as a reference is shown in Table 2 . In 22 tests done at different times during a 3-yr period, the mean MID on this vaccine was 0.018 ml with a range of 0.011 to 0.027 ml and a standard deviation of 0.0049 ml. (Tables 1 and 2) .
Neutralizing antibody levels. Serum neutralizing antibody titers were determined at different times on pooled sera of mice after receiving two doses of the 1:20 dilution of a vaccine, some challenged and others not. Animals were sacrificed to obtain blood on days 4, 7, 11, and 15. Results are shown in Table 4 . The pooled serum sample showed hardly any neutralizing effect on day 4, but a significant level of 1:30 was found on day 7. This titer appeared to drop rapidly to 1:7 on day 11 and to 1:5 on day 15 in those mice held without challenge. Those challenged at the normal interval of 7 days after the first injection of vaccine experienced a rapid boosting effect to 1:90 on day 11, then the titer appeared to drop to 1: 34 on day 15. The heat stability of this neutralizing antibody was demonstrated by retest after heating the serum for 30 min at 56 C.
Immunoglobulin M and immunoglobuin G activity. The early development of neutralizing antibodies and their short duration led us to study the type of antibody present. Antibody titers were determined before and after heating and after treatment with 2-ME on the 7th, 11th, and 15th day of bleedings without challenge after two doses of undiluted vaccine. After challenge, bleeding was on day 11 only. A comparison of ip challenge with ic challenge with only two lots of vaccine provided evidence that the two methods detected a difference in the same direction, but no more exact comparison was attempted. Theoretically, the ic test would appear to be less exact and perhaps not as meaningful since the virus bypasses most circulating antibody and other body defenses.
One of our misgivings about the ip test has been the possible role of nonspecific resistance to the challenge produced by giving the two doses of vaccine ip prior to challenge by the same route. In experiments not reported here, we found that other peripheral routes of challenge, subcutaneous and im, were significantly less effective and consistent. Thus, we gave the vaccine by the im route and used ip challenge. Since no other vaccine was used as a control, the degree of nonspecific resistance afforded by the ip injections of vaccine was not measured, but it was apparent that im injections of the same amount of antigen as given ip were less effective in the test employed and, of greatest importance, gave less concistent results. Since the amount of vaccine that can be given with accurate quantitation by this route in a mouse is restricted, it did not seem practical to pursue this aspect further.
In an attempt to understand the mechanism of protection in the ip mouse potency test, the vaccinated mice were examined for neutralizing antibody and interferon. The quantitative and qualitative antibody response of the mice appears quite clear, as might be expected. Antibody of unchallenged mice began to appear by the fourth day, peaked somewhere between the fourth and the 11th day as shown by a level of 1:30 to 1:100 on the 7th day, depending on the concentration of vaccine used, and was lower on the 11th day. Apparently this was immunoglobulin (Ig) M on the 7th day since it was completely 2-ME sensitive. A small amount of IgG began to appear on the 11th and 15th days, but the amount was minimal. After the stimulus of challenge in those bled on day 11, the titer rose significantly, but this was still an IgM response and thus not a true anamnestic type response. We are not surprised with the rapidity of the IgM titer fall shown by the unchallenged mice, since the half-life of mouse antibody is very short as compared to other animal species. Dixon et al. (5) reported the half-life of mouse immune gamma globulin to be 1.9 days only, when injected in an homologous system. Recent studies of Takeya and Nomoto (16) also suggest similar characteristics of IgM antibody response in mice. In their experiments with 90-day-old mice, they observed that peak antibody titers developed on about the 7th day followed by a continuous drop till the 13th day. With 10-day-old mice, the pattern of total antibody formation and the peak were somewhat similar, but these young mice did not develop 2-mercaptoethanol-resistant antibodies until 13 days. In view of these findings, the interesting question posed here with the mouse potency test, and as yet unanswered, is whether the rapid elevation of titer after challenge played a role in giving increased protection to the animal or whether protection was adequate from the vaccine alone. A graded challenge might help to clarify this.
Interferon apparently played no role in the protection of the mice, under the given experimental conditions (14) . The immunization of the mice may have a suppressing effect on the production of circulating interferon as induced by the challenge virus. Whether the minor interferon response detected 24 hr after the virus challenge played any role at all cannot be stated, but obviously the much greater response detected at both 6 and 24 hr in the unvaccinated mice failed to protect them. Thus, any effect it might have had in the vaccinated animals must have been extremely minimal.
Apparently this test is a valid measure of immunizing potential, even though the interval before the challenge is short, but it reduces the period required for testing the vaccine. Seroconversion alone may or may not be a sufficient criterion of effectiveness, but this point has not been established.
